Genmab says phase 2 trial shows 67% response rate for epcoritamab monotherapy in elderly newly diagnosed DLBCL patients

• Genmab disclosed new epcoritamab data in first-line DLBCL for elderly or comorbid patients with limited chemotherapy options.
• Results were presented at the 2026 EHA Congress; full monotherapy findings were also published in The Lancet Haematology.
• In a Phase 2 monotherapy study, treatment produced early responses with many patients reaching complete remission; remissions generally held up over follow-up.
• In a Phase 1b/2 study with epcoritamab plus R-mini-CHOP, most patients responded, many achieved complete remission, MRD clearance was sustained.
• Safety was broadly consistent with prior epcoritamab experience; infection risk and immune-related events remained key tolerability considerations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 202606131245BIZWIRE_USPR_____20260610_BW278575) on June 13, 2026, and is solely responsible for the information contained therein.